Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the women's environment, cancer and radiation epidemiology study Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Hormonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Estrogen Receptor Modulators
  • Neoplasms, Second Primary
  • Ovary
  • Tamoxifen

abstract

  • The associations between chemotherapy and tamoxifen treatment and reduced risk for contralateral breast cancer appear to continue for 10 and 5 years, respectively, after the initial breast cancer is diagnosed. Ovarian suppression may have a role in the association between chemotherapy and reduced risk for contralateral breast cancer.

authors

publication date

  • January 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1093/jnci/djm267

PubMed ID

  • 18159070

Additional Document Info

start page

  • 32

end page

  • 40

volume

  • 100

number

  • 1